Pharmacopeia, Consumer Lab priligy results There has been a continuing decline in breast cancer mortality over the last 10 years, which is partly due to the continued development of new therapy options for breast cancer, including the third generation aromatase inhibitors letrozole, anastrozole, and exemestane as the hormonal therapies of choice for postmenopausal patients Coombes et al, 2004; ATAC Trialists Group, 2005; Goss et al, 2005; The Breast International Group BIG 1 98 Collaborative Group, 2005